Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2
- PMID: 32511692
- PMCID: PMC7281356
- DOI: 10.1001/jama.2020.10369
Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2
Abstract
Importance: In communities with high rates of coronavirus disease 2019, reports have emerged of children with an unusual syndrome of fever and inflammation.
Objectives: To describe the clinical and laboratory characteristics of hospitalized children who met criteria for the pediatric inflammatory multisystem syndrome temporally associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (PIMS-TS) and compare these characteristics with other pediatric inflammatory disorders.
Design, setting, and participants: Case series of 58 children from 8 hospitals in England admitted between March 23 and May 16, 2020, with persistent fever and laboratory evidence of inflammation meeting published definitions for PIMS-TS. The final date of follow-up was May 22, 2020. Clinical and laboratory characteristics were abstracted by medical record review, and were compared with clinical characteristics of patients with Kawasaki disease (KD) (n = 1132), KD shock syndrome (n = 45), and toxic shock syndrome (n = 37) who had been admitted to hospitals in Europe and the US from 2002 to 2019.
Exposures: Signs and symptoms and laboratory and imaging findings of children who met definitional criteria for PIMS-TS from the UK, the US, and World Health Organization.
Main outcomes and measures: Clinical, laboratory, and imaging characteristics of children meeting definitional criteria for PIMS-TS, and comparison with the characteristics of other pediatric inflammatory disorders.
Results: Fifty-eight children (median age, 9 years [interquartile range {IQR}, 5.7-14]; 20 girls [34%]) were identified who met the criteria for PIMS-TS. Results from SARS-CoV-2 polymerase chain reaction tests were positive in 15 of 58 patients (26%) and SARS-CoV-2 IgG test results were positive in 40 of 46 (87%). In total, 45 of 58 patients (78%) had evidence of current or prior SARS-CoV-2 infection. All children presented with fever and nonspecific symptoms, including vomiting (26/58 [45%]), abdominal pain (31/58 [53%]), and diarrhea (30/58 [52%]). Rash was present in 30 of 58 (52%), and conjunctival injection in 26 of 58 (45%) cases. Laboratory evaluation was consistent with marked inflammation, for example, C-reactive protein (229 mg/L [IQR, 156-338], assessed in 58 of 58) and ferritin (610 μg/L [IQR, 359-1280], assessed in 53 of 58). Of the 58 children, 29 developed shock (with biochemical evidence of myocardial dysfunction) and required inotropic support and fluid resuscitation (including 23/29 [79%] who received mechanical ventilation); 13 met the American Heart Association definition of KD, and 23 had fever and inflammation without features of shock or KD. Eight patients (14%) developed coronary artery dilatation or aneurysm. Comparison of PIMS-TS with KD and with KD shock syndrome showed differences in clinical and laboratory features, including older age (median age, 9 years [IQR, 5.7-14] vs 2.7 years [IQR, 1.4-4.7] and 3.8 years [IQR, 0.2-18], respectively), and greater elevation of inflammatory markers such as C-reactive protein (median, 229 mg/L [IQR 156-338] vs 67 mg/L [IQR, 40-150 mg/L] and 193 mg/L [IQR, 83-237], respectively).
Conclusions and relevance: In this case series of hospitalized children who met criteria for PIMS-TS, there was a wide spectrum of presenting signs and symptoms and disease severity, ranging from fever and inflammation to myocardial injury, shock, and development of coronary artery aneurysms. The comparison with patients with KD and KD shock syndrome provides insights into this syndrome, and suggests this disorder differs from other pediatric inflammatory entities.
Conflict of interest statement
Figures
Comment in
-
SARS-CoV-2-Related Inflammatory Multisystem Syndrome in Children: Different or Shared Etiology and Pathophysiology as Kawasaki Disease?JAMA. 2020 Jul 21;324(3):246-248. doi: 10.1001/jama.2020.10370. JAMA. 2020. PMID: 32511667 No abstract available.
-
Update on the COVID-19-associated inflammatory syndrome in children and adolescents; paediatric inflammatory multisystem syndrome-temporally associated with SARS-CoV-2.J Paediatr Child Health. 2020 Aug;56(8):1173-1177. doi: 10.1111/jpc.15049. Epub 2020 Jul 31. J Paediatr Child Health. 2020. PMID: 32735721 Free PMC article.
Similar articles
-
Intensive care admissions of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study.Lancet Child Adolesc Health. 2020 Sep;4(9):669-677. doi: 10.1016/S2352-4642(20)30215-7. Epub 2020 Jul 9. Lancet Child Adolesc Health. 2020. PMID: 32653054 Free PMC article.
-
Defining Kawasaki disease and pediatric inflammatory multisystem syndrome-temporally associated to SARS-CoV-2 infection during SARS-CoV-2 epidemic in Italy: results from a national, multicenter survey.Pediatr Rheumatol Online J. 2021 Mar 16;19(1):29. doi: 10.1186/s12969-021-00511-7. Pediatr Rheumatol Online J. 2021. PMID: 33726806 Free PMC article.
-
Paediatric Inflammatory Multisystem Syndrome: Temporally Associated with SARS-CoV-2 (PIMS-TS): Cardiac Features, Management and Short-Term Outcomes at a UK Tertiary Paediatric Hospital.Pediatr Cardiol. 2020 Oct;41(7):1391-1401. doi: 10.1007/s00246-020-02391-2. Epub 2020 Jun 12. Pediatr Cardiol. 2020. PMID: 32529358 Free PMC article.
-
Delineating phenotypes of Kawasaki disease and SARS-CoV-2-related inflammatory multisystem syndrome: a French study and literature review.Rheumatology (Oxford). 2021 Oct 2;60(10):4530-4537. doi: 10.1093/rheumatology/keab026. Rheumatology (Oxford). 2021. PMID: 33493353 Free PMC article. Review.
-
Shock and Myocardial Injury in Children With Multisystem Inflammatory Syndrome Associated With SARS-CoV-2 Infection: What We Know. Case Series and Review of the Literature.J Intensive Care Med. 2021 Apr;36(4):392-403. doi: 10.1177/0885066620969350. Epub 2020 Nov 5. J Intensive Care Med. 2021. PMID: 33148089 Review.
Cited by
-
Evaluation of clinical and laboratory findings in MIS-C patients associated with COVID-19: An experience from the Northwest of Iran.PLoS One. 2024 Nov 21;19(11):e0313843. doi: 10.1371/journal.pone.0313843. eCollection 2024. PLoS One. 2024. PMID: 39570835 Free PMC article.
-
Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With COVID-19 Infection in Morocco.Glob Pediatr Health. 2024 Oct 28;11:2333794X241286772. doi: 10.1177/2333794X241286772. eCollection 2024. Glob Pediatr Health. 2024. PMID: 39493464 Free PMC article.
-
Post-COVID-19 Multisystem Inflammatory Syndrome in Adults (MIS-A) With Elevated Levels of Soluble Urokinase Plasminogen Activator Receptor (suPAR) Treated With Anakinra: A Case Report.Cureus. 2024 Oct 4;16(10):e70848. doi: 10.7759/cureus.70848. eCollection 2024 Oct. Cureus. 2024. PMID: 39493146 Free PMC article.
-
A Comparison of Kawasaki Disease during the SARS-CoV-2 Pandemic with Multisystem Inflammatory Syndrome in Children.Children (Basel). 2024 Sep 28;11(10):1185. doi: 10.3390/children11101185. Children (Basel). 2024. PMID: 39457150 Free PMC article.
-
Characteristics of COVID-19-associated multisystemic inflammatory syndrome in children treated in a Peruvian hospital, 2020-2022.Rev Peru Med Exp Salud Publica. 2024 Oct 21;41(3):301-308. doi: 10.17843/rpmesp.2024.413.13736. Rev Peru Med Exp Salud Publica. 2024. PMID: 39442113 Free PMC article.
References
Publication types
MeSH terms
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous

